Press Releases

INOVIO to Present at Upcoming Scientific Conferences

Posted on April 18, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

Posted on April 18, 2025

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Posted on April 18, 2025

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Posted on April 18, 2025

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Posted on April 18, 2025

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Posted on April 18, 2025

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Posted on April 18, 2025

INOVIO Announces Pricing of $30 Million Public Offering

Posted on April 18, 2025

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Posted on April 18, 2025

INOVIO Announces Proposed Public Offering

Posted on April 18, 2025

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.